Clinical Study | Office of Clinical Research

An Exploratory Phase II Study To Determine The Tolerability, Safety, And Activity Of A Novel Vasopressin 1A Receptor Antagonist (Srx246) In Irritabl

Posted Date: May 15, 2019

Investigator: Andrew Duker
Type of Study: Drug

We are doing this research to find out whether a new investigational drug called SRX246, which might be useful to HD patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth at doses as high as 160 mg. As part of this

Criteria:

We Are Asking You To Take Part In This Research Study Because You Have Huntington's Disease (Hd). Su

Keywords:

Huntingtons, Srx246, Neurology, Movement

For More Information:

Molly Winters
513-558-0269
molly.briggs@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List